A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Exclusion Criteria

• •They have a current or past diagnosis of schizoaffective disorder, schizophrenia, obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic disorder or mental retardation
• •They have a current diagnosis of major depressive episode, generalized anxiety disorder (GAD), or post-traumatic stress disorder (PTSD) or has a clinically significant sleep disorder requiring treatment
• •They require ongoing treatment or expected treatment with any psychotropic medication, including anxiolytics, antipsychotics, anticonvulsants, antidepressants, mood stabilizers, nicotine replacement therapies or varenicline
• •They require ongoing treatment or expected treatment with Coumadin
• •They failed to respond to two or more adequate trials of FDA-approved ADHD medication
• •They have taken atomoxetine during the last 3 months
• •They have violent, homicidal or suicidal ideation
• •They have a significant history of medical diagnoses, seizure disorder, Tourette's syndrome, traumatic brain injury, or a central nervous system (CNS) disease, excluding ADHD
• •They have a urine drug screen that is positive for alcohol or drugs of abuse
• •They have a history of substance or alcohol disorder during the last 3 months